Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease

American Journal of Hematology

Volumn 88, Issue 3, 2013, Pages 179-184

  Turkia, Hadhami Ben ^a   Gonzalez, Derlis E ^b   Barton, Norman W ^c   Zimran, Ari ^d   Kabra, Madhulika ^e   Lukina, Elena A ^f   Giraldo, Pilar ^g   Kisinovsky, Isaac ^h   Bavdekar, Ashish ⁱ   Dridi, Marie Françoise Ben ^a   Gupta, Neerja ^e   Kishnani, Priya S ^j   Sureshkumar, E K ^k   Wang, Nan ^c   Crombez, Eric ^c   Bhirangi, Kiran ^c   Mehta, Atul ^l  

^a LA RABTA HOSPITAL   (Tunisia)

^b Sanatorio Español   (Paraguay)

^c Shire Human Genetic Therapies Inc   (United States)

^d HEBREW UNIVERSITY   (Israel)

^e ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^f NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h Your Health SA   (Argentina)

ⁱ KEM HOSPITAL   (India)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k MALABAR INSTITUTE OF MEDICAL SCIENCES   (India)

^l ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; DRUG ANTIBODY; HEMOGLOBIN; IMIGLUCERASE; IMMUNOGLOBULIN G; VELAGLUCERASE ALFA;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTIBODY BLOOD LEVEL; ANTICONVULSANT THERAPY; ARTICLE; CHILD; CHILL; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSS REACTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZED CHILD; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SKIN ALLERGY; SPLENECTOMY; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLATELET COUNT; RECOMBINANT PROTEINS; SPLENECTOMY; TREATMENT OUTCOME;

EID: 84874328846     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23382     Document Type: Article

References (23)

1. Grabowski GA. Gaucher disease. Enzymology, genetics, and treatment. Adv Hum Genet 1993;21:377-441.
2. Cox TM, Schofield JP. Gaucher's disease: Clinical features and natural history. Baillieres Clin Haematol 1997;10:657-689.
3. Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33-39.
4. Brumshtein B, Salinas P, Peterson B, et al. Characterization of gene-activated human acid-beta-glucosidase: Crystal structure, glycan composition, and internalization into macrophages. Glycobiology 2010;20:24-32.
5. Takasaki S, Murray GJ, Furbish FS, et al. Structure of the N-asparagine-linked oligosaccharide units of human placental beta-glucocerebrosidase. J Biol Chem 1984;259:10112-10117.
6. Zimran A, Altarescu G, Philips M, et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010;115:4651-4656.
7. Mehta A. Epidemiology and natural history of Gaucher's disease. Eur J Intern Med 2006;17 Suppl:S2-S5.
8. ® imiglucerase for injection. Prescribing Information 2011. Available at: http://www.cerezyme.com, Accessed 13 August 2012.
9. Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, et al. Transglycosidase activity of chitotriosidase: Improved enzymatic assay for the human macrophage chitinase. J Biol Chem 2003;278:40911-40916.
10. Schoonhoven A, Rudensky B, Elstein D, et al. Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta 2007;381:136-139.
11. Boot RG, Verhoek M, de Fost M, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention. Blood 2004;103:33-39.
12. Sellos-Moura M, Barzegar S, Pan L, et al. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease. J Immunol Methods 2011;373:45-53.
13. Ludwig J. Current Methods of Autopsy Practice. Philadelphia: W. B. Saunders; 1979. pp 676-685.
14. Hill SC, Damaska BM, Ling A, et al. Gaucher disease: Abdominal MR imaging findings in 46 patients. Radiology 1992;184:561-566.
15. Stein P, Malhotra A, Haims A, et al. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy. J Inherit Metab Dis 2010;33:769-774.
16. Goker-Alpan O, Hruska KS, Orvisky E, et al. Divergent phenotypes in Gaucher disease implicate the role of modifiers. J Med Genet 2005;42:e37.
17. Ida H, Rennert OM, Iwasawa K, et al. Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation. Hum Genet 1999;105:120-126.
18. Patterson MC, Horowitz M, Abel RB, et al. Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease. Neurology 1993;43:1993-1997.
19. Altarescu G, Hill S, Wiggs E, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 2001;138:539-547.
20. Starzyk K, Richards S, Yee J, et al. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab 2007;90:157-163.
21. Rosenberg M, Kingma W, Fitzpatrick MA, et al. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999;93:2081-2088.
22. Hollak CE, vom Dahl S, Aerts JM, et al. Force majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 2010;44:41-47.
23. Sirrs S. The Fabrazyme shortage-A call to action for metabolic physicians. Mol Genet Metab 2010;102:4-5.